Review Article

Presage of oncolytic virotherapy for oral cancer with herpes simplex virus

Yoshiaki Yura*

Department of Oral and Maxillofacial Surgery II, Osaka University, Graduate School of Dentistry, 1-8 Yamadaoka, Suita, Osaka 565-0871, Japan

Received 17 May 2016; received in revised form 2 October 2016; accepted 8 October 2016

Summary A virus is a pathogenic organism that causes a number of infectious diseases in humans. The oral cavity is the site at which viruses enter and are excreted from the human body. Herpes simplex virus type 1 (HSV-1) produces the primary infectious disease, gingivostomatitis, and recurrent disease, labial herpes. HSV-1 is one of the most extensively investigated viruses used for cancer therapy. In principle, HSV-1 infects epithelial cells and neuronal cells and exhibits cytotoxicity due to its cytopathic effects on these cells. If the replication of the virus occurs in tumor cells, but not normal cells, the virus may be used as an antitumor agent. Therefore, HSV-1 genes have been modified by genetic engineering, and in vitro and in vivo studies with the oncolytic virus have demonstrated its efficiency against head and neck cancer including oral cancer. The oncolytic abilities of other viruses such as adenovirus and reovirus have also been demonstrated. In clinical trials, HSV-1 is the top runner and is now available for the treatment of patients with advanced melanoma. Thus, melanoma in the oral cavity is the target of oncolytic HSV-1. Oncolytic virotherapy is a hopeful and realistic modality for the treatment of oral cancer.

© 2016 The Author(s). Published by Elsevier Ltd on behalf of Japanese Association for Dental Science. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

KEYWORDS
Herpes simplex virus; Oncolytic virotherapy; Oral cancer

Contents

1. Introduction ................................................................................................................. 54
2. Development of an oncolytic virus ........................................................................... 55
  2.1. Genetic engineering of HSV-1 .............................................................................. 55
  2.2. Fusogenic HSV-1 .................................................................................................... 56

* Fax: +81 0742 35 6824.
E-mail addresses: narayura630@gmail.com, narayura@m3.kcn.ne.jp

http://dx.doi.org/10.1016/j.jdsr.2016.10.001
1882-7616/© 2016 The Author(s). Published by Elsevier Ltd on behalf of Japanese Association for Dental Science. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction

Head and neck cancer accounts for 6% of all malignancies worldwide. Oral cancer is included in head and neck cancer, is the fifteenth most common malignancy globally, and accounts for approximately 1% of all malignancies in Japan. Most cases of oral cancer are squamous cell carcinoma (SCC). Surgery, radiation, chemotherapy and the combination of these modalities are common therapeutic methods to treat patients. The therapeutic effects of chemoradiotherapy using cisplatin markedly improved 5-year overall survival over radiotherapy alone; however, survival rates in advanced cases are still low [1,2]. A recent aspect is the introduction of molecular target therapy using an antibody against the epidermal growth factor receptor (EGFR), cetuximab. The treatment of locoregional advanced head and neck cancer with concomitant high-dose radiotherapy plus cetuximab has improved locoregional control and reduced mortality [3], although cisplatin-based chemoradiotherapy remains the standard of care until equivalence with radiotherapy plus cetuximab is reproducibly demonstrated [4].

Immunotherapy with biological response modifiers (BRMs) including OK-432 (picibanil) and BCG has been used to enhance antitumor immunity and biological responses have been reported; however, their effects on tumor immunity have been non-specific [5]. Tumor antigen-specific vaccinations have since been perceived as a potentially effective approach to improve outcomes by mobilizing antitumor immunity and reversing immune escape in cancer patients. Phase 1 studies using survivin-derived peptides and p53 peptide vaccines for patients with head and neck cancer were found to be safe and achieved moderate clinical outcomes [6,7]. On the other hand, efforts to restore latent antitumor immunity have focused on antibody-based interventions targeting cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1) on T cells and its principal ligand (PD-L1) on tumor cells. The immune checkpoint inhibitor to either PD-1 or PD-L1 has produced significant antitumor activity with markedly less toxicity than the CTLA-4 Inhibitor. In clinical trials on these immune checkpoint inhibitors, positive responses were observed in patients with melanoma, renal cancer, lung cancer, bladder cancer, and head and neck cancer [8,9].

Another recent advance in cancer treatments is the use of viruses that destroy tumors, i.e., oncolytic viruses. Since some viruses exhibit oncolytic abilities, attempts to use viruses as antitumor agents were made in the 1950s [10]. In Japan, the mumps virus was used and clinical effects were observed in 37 out of 90 terminal cancer patients; however, further clinical studies were not performed [11]. On the other hand, a virus is the most reliable vector to transfer human genes into deficient individuals. In 1990, a clinical trial on gene therapy was initiated to transfer the adenovirus deaminase (ADA) gene into the T cells of two children with severe combined immunodeficiency using a retrovirus to deliver the gene [12]. Gene therapy was also applied to the treatment of cancer. For example, the wild-type tumor suppressor gene p53 carrying a retrovirus or adenovirus was introduced into lung cancer patients in whom the p53 gene was mutated in order to restore the function of wild-type p53 [13,14]. Repeated intratumoral injections of adenovirus (Ad-p53) were tolerated well, resulted in the transcripts expression of wild-type p53, and appeared to mediate antitumor activity in a subset of patients with advanced lung cancer. Viruses for gene therapy are generally replication-restricted in order to prevent the endless spread of viral infection in the body. A virus infects appropriate target cells, introduces genes into the cells, and its replication is then terminated. Target cells that acquire a tumor suppression gene are destroyed by the action of the gene, whereas cells devoid of the infection survive, and its effect on cancer is gradually lost, resulting in the failure of this therapy. This is a limitation of replication-restricted viruses. As a next step, replication-competent viruses were reconsidered as a tool to destroy a larger number of tumor cells by inoculated viruses and progeny viruses (Fig. 1). This concept was proposed by Martuza, a doctor of neurosurgery [15]. Mar-
Oncolytic virotherapy for oral cancer

Figure 2  Schematic representation of the genomic structure of oncolytic HSV-1. TRL, terminal repeat of the L component; UL, the L component; IRL, internal repeat of the L component; IRS, internal repeat of the S component; US, the S component; TRS, terminal repeat of the S component; GM-CSF, granulocyte macrophage colony-stimulating factor; ICP, infected cell protein.

tuza et al. attempted to destroy tumors in a glioma model using herpes simplex virus type 1 (HSV-1) in which the thymidine kinase (TK) gene was deleted by genetic engineering. This is the first published study to treat tumors with a modified replication-competent virus and the method was later called oncolytic virotherapy. HSV-1 frequently infects the oral mucosa and produces the primary infectious disease, gingivostomatitis, and recurrent disease, labial herpes. HSV-1 is one of the most extensively investigated viruses used for cancer therapy [16–20]. In this review, the development of viruses for use as a treatment of head and neck cancer including oral cancer is discussed with a focus on oncolytic HSV-1.

2. Development of an oncolytic virus

2.1. Genetic engineering of HSV-1

Since Martuza et al. published their work indicating that an engineered HSV-1 is applicable to the treatment of brain tumors, a number of viruses were considered to be oncolytic viruses for solid tumors. The major oncolytic DNA viruses are HSV, adenovirus, and vaccinia virus, and RNA viruses are coxsackie virus, reovirus, measles virus, Newcastle disease virus (NDV), and vesicular stomatitis virus (VSV) [16–23]. Oncolytic viruses may infect and replicate in tumor cells to produce progeny viruses, which is followed by the destruction of host tumor cells. If the progeny virus infects inherently susceptible cells and induces infectious disease, the treatment is not acceptable because the spread of infection must be limited to tumors. The initial HSV-1 vector tested was a TK gene-deficient mutant of HSV-1 [15]. However, the TK gene coded by the L component (UL) 23 of the HSV-1 genome is essential for the selective effects of the anti-herpes virus drug, aciclovir [24]; therefore, viral genes other than TK must be modified in subsequently developed oncolytic HSV-1s. Since the γ134.5 gene was found to be responsible for the neurovirulence of HSV-1 [25], HSV-1 vectors that were deficient in the γ134.5 gene were constructed. They were R3616, R489, HSV1716, NV1020, and G207 derived from wild-type HSV-1 strain F [26] (Fig. 2). When the γ134.5 gene was deleted, the ability of the virus to induce encephalitis was lost, even if the virus was directly injected into the brain. Moreover, the γ134.5 gene has been shown to play a major role in the selective targeting of tumor cells in HSV-1-mediated virotherapy. An infection with HSV-1 induces an interferon reaction, which activates double-stranded RNA-dependent protein kinase (PKR). PKR phosphorylates eukaryotic initiation factor 2 α (eIF-2α), which is essential for the translation of mRNA, resulting in the total shutdown of protein synthesis. The HSV-1 γ134.5 gene acts as a phosphatase accessory factor that recruits protein phosphatase 1α in order to dephosphorylate eIF-2α. As a consequence, protein synthesis continues unimpeded in cells in which HSV-1 expresses the γ134.5 gene. Thus, if the γ134.5 gene is deleted, the virus does not replicate in normal cells in which PKR is activated after infection by the virus. However, it was found that this mutant had the ability to replicate in tumor cells. The mechanisms responsible are not yet clear; however, RAS signals and down-stream mitogen-activated protein kinase (MAPK) kinase (MEK) may be activated in tumor cells constitutionally. These activated kinases block the activation of PKR by the HSV-1 infection such that the γ134.5 gene-deficient virus replicates in tumor cells, but not normal cells [27,28]. The efficiency of γ134.5 gene-deficient HSV-1 against tumors was demonstrated in basic and clinical studies without the induction of encephalitis [26,29–31]. Furthermore, another gene that encodes ribonucleotide reductase (RR) was modified to improve the specificity of viruses against tumor cells. RR is essential for viral replication and is provided by the host cell or virus itself; therefore, RR-dependent HSV-1 is permitted to replicate in proliferating tumor cells with RR activity only at a high level. HSV-1 with double mutations in the γ134.5 gene and UL39 gene encoding infected cell protein (ICP) 6 (RR) was subsequently constructed to decrease adverse effects; however, the killing effect of the virus was partly impaired [32]. It exerted cytotoxic effects on tumor
Table 1  Oncolytic HSV-1 investigated for its oncolytic ability to head and neck cancer.

| Name                  | Modification                              | Clinical trial (HNSCC) | References |
|-----------------------|-------------------------------------------|------------------------|------------|
| R849                  | γ1 34.5 deleted, with LacZ                | Phase I                | [39, 64]  |
| HSV1716               | γ1 34.5 deleted                           |                        | [49]       |
| NV1020                | One copy of γ1 34.5 deleted HSV-1/HSV-2 intertypic recombinant |                        | [31]       |
| G207                  | γ1 34.5 and ICP6 (UL39) deleted           |                        | [33]       |
| G47 delta             | γ1 34.5, ICP6 (UL39), and ICP47 (US12) deleted |                        | [44]       |
| Talimogene laherparepvec (T-Vec); OncoVEXGM-CSF | γ1 34.5 and ICP47 (US12) deleted, with human GM-CSF | Phase I/II             | [52]       |
|  (glycoproteins, CD)  |                                           |                        |            |
| OncoVEX GALV/CD       | γ1 34.5 and ICP47 (US12) deleted, with CD |                        | [35]       |
| HF10                  | Mutations (glycoproteins, UL56)           | Phase I                | [54]       |
| RH2                   | Mutations (gB, gD), γ1 34.5 deleted R849/HF recombinant |                        | [40, 41]  |

HNSCC, head and neck squamous cell carcinoma; GM-CSF, granulocyte macrophage colony-stimulating factor; GALV, gibbon ape leukemia virus; CD, cytosine deaminase.

2.2. Fusogenic HSV-1

Several viruses have been shown to destroy their target cells through multinucleated syncytial formation, a process involving membrane fusion between infected and un-infected cells. The viral components that contribute to syncytial formation are mainly fusogenic membrane glycoproteins (FMGs). In order to efficiently spread the viral infection around the surrounding tumor cells, the FMG gene from gibbon ape leukemia virus (GALV) was inserted into the HSV-1 genome. The virus caused strong cell membrane fusion and significantly increased the potency of viral oncolysis [34]. HSV-1 expressing cytosine deaminase (CD) and FMG was reported to exert its lytic effects on head and neck SCC cells at a relatively low viral dose, whereas prodruk conversion by CD did not necessarily enhance therapy at doses that caused efficient cytotoxicity [35]. HF10, a clone of the spontaneously occurring and highly attenuated laboratory strain HF, induced extensive cell fusion and formed syncytia composed of large multinucleate cells [36]. HF10 was less virulent than wild-type HSV-1 in mice and did not induce encephalitis when injected into a peripheral site in mice; however, a high-dose intracerebral injection induced encephalitis. The genome of HF10 has large deletions at both ends of the L-region, an extensive genomic rearrangement, and it lacks the expression of UL56 and latency-associated transcript (LAT). The glycoprotein mutations responsible for cell fusion and a UL56 deletion have been implicated in its low neurovirulence [37]. Since no foreign genes were introduced into the genome, HF10 has an advantage over viruses with genetic engineering in that permission has been obtained from the Japanese government for clinical studies [38]. A recombinant between R849, a γ1 34.5 gene-deficient HSV-1 in which the LacZ gene was inserted, and HF, the parental virus of HF10, was subsequently produced [39,40]. This recombinant HSV-1 RH2 is deficient in the γ1 34.5 gene and has more mutations than wild-type viruses; the full sequences of the viral genome have been published [41]. Variations in the genes glycoprotein B (gB) and glycoprotein D (gD) are considered to be responsible for the fusogenic property of this virus. RH2 replicates efficiently, produces large syncytia, and destroys human oral SCC cells [40]. It was also found to suppress the growth of oral SCC xenografts in nude mice without any pathological features in animals.

3. Antitumor immunity

Cancer immunotherapy has wide appeal because of its hypothetical ability to eradicate residual or metastatic tumors that are difficult to manage by conventional treatments. The generation of whole tumor vaccines through tumor destruction in vivo has the potential to release the entire reservoir of tumor antigens in their native forms and configurations. In addition to the tumoricidal effects of viruses, oncolytic virus-mediated tumor destruction may provide an in situ source of tumor antigens to stimulate antitumor immunity. This specific feature of oncolytic viruses that is responsible for tumor immunity was reported in the 1990s. An intratumoral injection of oncolytic HSV-1 into murine colorectal carcinoma or neuroblastoma induced a tumor-specific immune response in synergistic mice that subsequently contributed to a significant reduction in the size of contralateral non-inoculated tumors or established tumors in the brain [42]. A previous study reported that fusogenic HSV-1 Synco-2D directly induced the cytolysis of tumor cells by syncytial formation and was considered to induce strong antitumor immunity, because virus-uninjected local and metastatic lung tumors
were markedly smaller than those in control mice [43]. A novel oncolytic HSV-1 was subsequently produced in which the \( \gamma_1 \)34.5 gene was deleted to provide selective tumor cell proliferation, whereas the ICP 47 encoded by the S component (US)12 gene of the HSV-1 genome was deleted in order to enhance the antitumor response by antigen pre-sentation and tumor cell killing through the up-regulation of US11, which occurs following this mutation. G47 delta is a mutant that contains three mutations, i.e., \( \gamma_1 \)34.5, ICP6, and ICP47. Its antitumor effects on human nasopharyngeal carcinoma have been demonstrated in vitro and in vivo [44]. Furthermore, the gene of human granulocyte macrophage colony-stimulating factor (GM-CSF) was inserted into the HSV-1 vector backbone with the deletions of the \( \gamma_1 \)34.5 and ICP47 (US12) genes [45]. GM-CSF is a potent immune stimulator that promotes the differentiation of progenitor cells into dendritic cells. The combination of GM-CSF with oncolytic therapy may be particularly effective because cell death accompanying virus replication serves to release tumor antigens efficiently, which is required for GM-CSF-enhanced immune responses. The HSV-1 vector with GM-CSF was initially named OncoVEXGm-Csf and was changed to talimogene laherparepvec (T-Vec); its drug name is Imlygic (Fig. 2). The treatment of disseminated peritoneal tumors with HF10 has been shown to induce specific antitumor immune responses [36]. The enhancing effects of R849/HF recombinant RH2 on tumor immunity were also demonstrated using a syngeneic mouse model. Two tumors were produced on the back of the C3H mouse and RH2 was injected into one tumor while the contralateral tumor was left untreated. Although the sup-
pression of RH2-injected tumors was significantly greater than that of uninjected tumors in the treated group, the suppression of contralateral tumors was also greater in the treated group than in the untreated group. Immune cell infiltration, particularly, CD8+ T cells played a major role in this immune response [46]. Furthermore, cell death with immunogenic potential, i.e., immunogenic cell death, was also demonstrated in RH2-infected SCC cells [47].

4. Clinical study

4.1. Adverse effects

Since viruses have been shown to effectively reduce tumor volumes in vivo, clinical trials have been undertaken using adenovirus, HSV-1, coxsackie virus, reovirus, HSV, vaccinia virus, and VSV. Adenovirus, reovirus, and HSV have been used in clinical studies for head and neck cancer [16, 20, 21, 23, 48, 49]. In a phase 1 study with HSV-1 G207 for recurrent malignant glioma, side effects were limited to mild to moderate febrile reactions and localized erythema-tous/inflammatory reactions at the injected sites of tumors [50]. While commonly referred to as influenza-like symp-
toms, side effects are generally milder, but may be more robust in patients who were seronegative for the parent-
oral viral species at their first dose or when a high viral dose is given by an intravenous route [23]. Safety issues with oncolytic agents are mostly the same as those for live attenu-
ated viral vaccines, and this is the general direction toward which regulatory requirements are moving, albeit with con-
siderable country-to-country variations.

![Figure 3](image)

**Figure 3** Treatment schedule of cisplatin-based chemoradio-
therapy with oncolytic HSV-1 as reported by Harrington et al. [52].

4.2. HSV-1 talimogene laherparepvec (T-Vec)

While case reports have described significant responses to oncolytic viruses in patients with disseminated diseases, only a small number of phase II/III trials have been published to date [51, 52]. The most recent of these and the first trial on oncolytic therapy to show its tangible bene-
fits is the phase III trial on HSV-1 T-Vec [53]. In this trial, patients with treated/untreated unresectable stage IIIB/C or stage IV melanoma were randomized 2:1 to receive intra-
tumoral T-Vec or subcutaneous recombinant GM-CSF. Among 436 patients, the durable responsible rate was significantly higher with T-Vec (16.3%) than with GM-CSF (2.1%). The over-
all response rate was also higher in the T-Vec arm (26.4%) than in the GM-CSF arm (5.7%). Median overall survival (OS) was 23.3 months with T-Vec and 18.9 months with GM-CSF (P = 0.051). The most common adverse events with T-Vec were fatigue, chills, and pyrexia. T-Vec was effective, par-
ticularly in untreated patients or those with stage IIIB, IIIC, or IV1a disease. The clinical effects of T-Vec were also investi-
gated in combination with radiotherapy and cisplatin in phase I/II study for patients with head and neck cancer in untreated stage III/IV [52] (Fig. 3). Seventeen patients were en-
rolled. Patients received chemoradiotherapy (70 Gy in 35 fractions with concomitant cisplatin 100 mg/m² on days 1, 22, and 43) and dose-escalating T-Vec by an intratumoral injection on days 1, 22, 43, and 64. In this study, the intratu-
moral injection means an injection of T-Vec into metastatic lymph nodes. Patients underwent neck dissection 6–8 weeks after the end of chemoradiotherapy. Locoregional control was achieved in all patients, with a 76.5% relapse-free rate. Disease-specific survival was 82.4% at a median follow-up of 29 weeks (range, 19–40 months).

4.3. HSV-1 HF10

HF10 was demonstrated to be effective as an oncolytic agent using various murine tumor models, including melanoma, metastatic breast cancer, bladder cancer, ovarian cancer, sarcoma, and colorectal cancer [18]. An intratumoral injec-
tion of HF10 was performed in a small number of Japanese patients with recurrent breast cancer and head and neck cancer without significant adverse effects. Metastatic skin nodules (lymph node metastasis) of head and neck cancer
were injected with HF10 once a day for 3 days. HF10 replicated in the tumors, spread well in the tumor nodules, and caused cell death in a large population of tumor cells [54]. In a phase 1 clinical trial for unresectable pancreatic cancer, HF10 was injected intratumorally 3 times and exhibited some therapeutic potential. Tumor responses were classified as stable disease in 3 patients, a partial response in 1 patient, and progressive disease in 2 patients [55].

5. New combination therapy

5.1. Oncolytic virus and immune checkpoint inhibitors

Antibodies targeting CTLA-4 and PD-1/PDL-1 are already used clinically for a range of malignancies, including melanoma, and have had very positive effects. Melanoma antigen-specific vaccines have been evaluated in early phase clinical trials in adjuvant settings and were found to increase the expression of PD-1 at the injection site. Similarly, there is emerging evidence to show that oncolytic viruses regulate the expression of PD1/PDL-1 in cancer cells, thereby providing a strong rational for combination therapy with immune checkpoint inhibitors. The combination of anti-PD-1 and reovirus led to longer survival than that with either agent alone [56]. An anti-PD-1 antibody treatment down-regulated regulatory T cell activity and increased effectiveness of NK-cell-mediated lysis in malignant cells infected with reovirus. In a phase I trial, the anti-CTLA-4 monoclonal antibody, ipilimumab, was combined with a poxvirus-based vaccine in patients with castrate-resistant prostate cancer [57]. The side effect profile did not appear to differ significantly over single agent therapy with ipilimumab. Most recently, encouraging findings have been reported from combination T-Vec with an anti-CTLA-4 antibody [58]. Ongoing T-Vec studies include evaluations in the safety and efficacy of T-Vec plus ipilimumab versus ipilimumab alone and T-Vec plus pembrolizumab (anti-PD-1) versus pembrolizumab alone [23].

5.2. A specific reagent to enhance the replication of oncolytic HSV-1

Certain agents have been shown to induce the differentiation of malignant cells [59]. Tumor cells committed to differentiate lose their ability to proliferate and propagate when transplanted into animals. Hexamethylene bisacetamide (HMBA), a compound structurally related to dimethyl sulfoxide, was found to induce the differentiation of erythroleukemia cells [60] and has been tested in patients with refractory solid tumors [61]. HMBA is of interest because it enhances the replication of wild-type HSV-1 in SCC cells and the addition of the compound facilitated the reactivation of HSV-1 or HSV-2 in animal models [62,63]. The replication of γ134.5 gene-deficient HSV-1 R849 in oral SCC cells was also enhanced in the presence of HMBA in oral SCC cells. In an animal study, the growth of nude mouse tumors was markedly suppressed by R849 in combination with HMBA and the survival of co-treated animals was significantly longer than that of animals treated with R849 only. HMBA enhances the antitumor activity of an inoculated virus through the expression of immediate early genes without increasing its toxicity [64]. It may be useful as an enhancing agent for oncolytic therapy with HSV-1 in cancer patients.

6. Conclusion

In oncolytic virotherapy, there are many hurdles that must still be overcome. They include selective virus replication in tumor cells, efficient virus delivery and intratumoral spread, stimulation of antitumor immunity, immune-mediated clearance of virion particles from patient body, limited ability of pre-clinical tumor model systems to actually predict the efficacy, and environmental viral shedding. Nevertheless, the mechanisms by which oncolytic HSV-1 exerts its antitumor effects are completely different from those of conventional and recent therapies with chemotherapeutic agents, radiation, peptide vaccines, and monoclonal antibodies targeting EGFR, CTLA-4, and PD-1/PD-L1; it induces cell lysis by viral replication in the tumor and releases tumor antigens to potentiate tumor immunity. In phase III clinical trials, oncolytic HSV-1 showed specific antitumor immunity and clinical responses in a significant fraction of melanoma patients. The synergistic and/or additive effects of oncolytic viruses have been demonstrated in combination with conventional modes of therapy. Based on encouraging evidence supporting the safety and potential efficacy of oncolytic viruses, there is a significant chance that viruses may become an entirely new modality for the treatment of oral cancer.

Conflict of interest

The authors declare that no conflicts of interest exist.

References

[1] Ahn MJ, D’Cruz A, Vermorken JB, Chen JP, Chitapanarux I, Dang HQ, et al. Clinical recommendations for defining platinum unsuitable head and neck cancer patient populations on chemoradiotherapy: a literature review. Oral Oncol 2016;53:10–6.
[2] Schwam ZG, Judson BL. Improved prognosis for patients with oral cavity squamous cell carcinoma: analysis of the National Cancer Database 1998–2006. Oral Oncol 2016;52:45–51.
[3] Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567–78.
[4] Petrelli F, Coinu A, Riboldi V, Borgonovo K, Ghirardi M, Cabiddu M, et al. Concomitant platinum-based chemotherapy or cetuximab with radiotherapy for locally advanced head and neck cancer: a systematic review and meta-analysis of published studies. Oral Oncol 2014;50:1041–8.
[5] Fukazawa H, Ohashi Y, Sekiyama S, Hoshi H, Abe M, Takahashi M, et al. Multidisciplinary treatment of head and neck cancer using BCG, OK-432, and GE-132 as biologic response modifiers. Head Neck 1994;16:30–8.
[6] Miyazaki A, Kobayashi J, Torigoe T, Hirohashi Y, Yamamoto T, Yamaguchi A, et al. Phase I clinicaltrial of survivin-derived peptide vaccine therapy for patients with advanced or recurrent oral cancer. Cancer Sci 2011;102:324–9.
[7] Schuler PJ, Harasymczuk M, Visus C, Deleo A, Trivedi S, Lei Y, et al. Phase I dendritic cell p53 peptide vaccine for head and neck cancer. Clin Cancer Res 2014;20:2433–44.
[8] Zandberg DP, Strome SE. The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck. Oral Oncol 2014;50:627—32.

[9] Philips GK, Atkins MT. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies. Int Immunol 2015;27:39—46.

[10] Moore AE. Viruses with oncolytic properties and their adaptation to tumors. Ann N Y Acad Sci 1952;54:945—52.

[11] Asada T. Treatment of human cancer with mumps virus. Cancer 1974;34:1907—28.

[12] Blaese RM, Culver KW, Miller AD, Carter CS, Fleisher T, Clerici M, et al. T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science 1995;270:475—80.

[13] Fujiwara T, Cai DW, Georges RN, Mukhopadhyay T, Grimm EA, Roth JA. Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J Natl Cancer Inst 1994;86:1458—62.

[14] Swisher SG, Roth JA, Nemunaitis J, Lawrence DD, Kemp BL, Carrasco CH, et al. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst 1999;91:763—71.

[15] Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 1991;252:854—6.

[16] Varghese S, Rabkin SD. Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther 2002;9:967—78.

[17] Vahä-Koskela MJ, Heikkilä JE, Hinkkanen AE. Oncolytic viruses in cancer therapy. Cancer Lett 2007;254:178—216.

[18] Watanabe D. Medical application of herpes simplex virus. J Dermatol Sci 2010;57:75—82.

[19] Campadelli-Fiame G, De Giovanni C, Gatta V, Nanni P, Lollini PL, Menotti L. Rethinking herpes simplex virus: the way to oncolytic agents. Rev Med Virol 2011;21:213—26.

[20] Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol 2012;30:658—70.

[21] Kyula JN, Roulistone V, Karapanagiotou EM, Melcher AA, Harrington KJ. Oncolytic reovirus type 3 (Bearing) as a novel therapy in head and neck cancer. Expert Opin Biol Ther 2012;12:1669—78.

[22] Turnbull S, West EJ, Scott KJ, Appleton E, Melcher A, Ralph C. Evidence for oncolytic virotherapy: where have we got to and where are we now? Curr Opin Virol 2015;13:93—100.

[23] Elion GB, Furman PA, Fyfe JA, de Miranda P, Beauchamp L, Schaeffer HJ. Selectivity of action of an antitherapeutic agent, 9-(2-hydroxyethyl)methyl] guanine. Proc Natl Acad Sci U S A 1977;74:5716—20.

[24] Chou J, Kern ER, Whitley RJ, Roizman B. Mapping of herpes simplex virus latency to mammalian cell genome by fluorescence in situ hybridization. Proc Natl Acad Sci U S A 1990;87:5716—20.

[25] Andreansky S, Sorocneau L, Flotte ER, Chou J, Markert JM, Gillespie GY, et al. Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. Cancer Res 1997;57:1502—9.

[26] Farassati F, Yang AD, Lee PW. Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1. Nat Cell Biol 2001;3:745—50.

[27] Smith KD, Mezirii J, Bickenbach K, Veerapong J, Charron J, Posner MC, et al. Activated MEK suppresses activation of PKR and enables efficient replication and in vivo oncolysis by Deltagamma(1)34.5 mutants of herpes simplex virus 1. J Virol 2006;80:1110—20.

[28] MacLean AR, ul-Forayed M, Robertson L, Harland J, Brown SM. Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the 'a' sequence. J Gen Virol 1991;72:631—9.

[29] Whitley RJ, Kern ER, Chatterjee S, Chou J, Roizman B. Replication, establishment of latency, and induced reactivation of herpes simplex virus gamma 1 34.5 deletion mutants in rodent models. J Clin Invest 1993;91:2387—43.

[30] Wong RJ, Kim SH, Joe JK, Shah JP, Johnson PA, Fong Y. Effective treatment of head and neck squamous cell carcinoma by an oncolytic herpes simplex virus. J Am Coll Surg 2001;193:12—21.

[31] Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1995;1:938—43.

[32] Carew JF, Kooby DA, Haltermann MW, Fedoroff HJ, Fong Y. Selective infection and cytolysis of human head and neck squamous cell carcinoma with sparing of normal mucosa by a cytopathic herpes simplex virus type 1 (G207). Hum Gene Ther 1999;10:599—606.

[33] Fu X, Zhang X. Potent systemic antitumor activity from an oncolytic herpes simplex virus of syncytial phenotype. Cancer Res 2002;62:2306—12.

[34] Price DL, Lin SF, Han Z, Simpson G, Coffin RS, Wong J, et al. Oncolyis using herpes simplex virus type 1 engineered to express cytosine deaminase and a fusogenic glycoprotein for head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2010;136:151—8.

[35] Takakuwa H, Goshima F, Nozawa N, Yoshikawa T, Kimata H, Nakao A, et al. Oncolytic viral therapy using a spontaneously generated herpes simplex virus type 1 variant for disseminated peritoneal tumor in immunocompetent mice. Arch Virol 2003;148:813—25.

[36] Ushijima Y, Luo C, Goshima F, Yamauchi Y, Kimura H, Nishiyama Y. Determination and analysis of the DNA sequence of highly attenuated herpes simplex virus type 1 mutant HF10, a potent oncolytic virus. Microbes Infect 2007;9:142—9.

[37] Nakao A, Kimata H, Imai T, Kikumori T, Teshigahara O, Nagasaka T, et al. Intratumoral injection of herpes simplex virus HF10 in recurrent breast cancer. Ann Oncol 2004;15:988—9.

[38] Ogawa F, Takaoka H, Iwai S, Aota K, Yura Y. Combined oncolytic virotherapy with herpes simplex virus for oral squamous cell carcinoma. Anticancer Res 2008;28:3637—45.

[39] Takaoka H, Takahashi G, Ogawa F, Imai T, Iwai S, Yura Y. A novel fusogenic herpes simplex virus for oncolytic virotherapy of squamous cell carcinoma. Virol J 2011;8:294.

[40] Takahashi G, Meshii N, Hamada M, Iwai S, Yura Y. Sequence of a fusogenic herpes simplex virus, RH2, for oncolytic virotherapy. J Gen Virol 2013;94:726—37.

[41] Toda M, Rabkin SD, Kojima H, Martuza RL. Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum Gene Ther 1999;10:385—93.

[42] Nakamori M, Fu X, Rousseau R, Chen SY, Zhang X. Destruction of nonimmunogenic mammary tumor cells by a fusogenic oncolytic herpes simplex virus induces potent anti-tumor immunity. Mol Ther 2004;9:658—65.

[43] Wang JN, Hu P, Zeng MS, Liu RB. Anti-tumor effect of oncolytic herpes simplex virus G47 delta on human nasopharyngeal carcinoma. Chin J Cancer 2011;30:831—41.

[44] Liu BL, Robinson M, Han ZQ, Branston RH, English C, Reay P, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther 2003;10:292—303.

[45] Meshii N, Takahashi G, Okuzumi S, Hamada M, Iwai S, Takasu A, et al. Enhancement of systemic tumor immunity for squamous cell carcinoma cells by an oncolytic herpes simplex virus. Cancer Gene Ther 2013;20:493—8.

[46] Takasu A, Masui A, Hamada M, Imai T, Iwai S, Yura Y. Immunogenic cell death by oncolytic herpes simplex virus type 1 in squamous cell carcinoma cells. Cancer Gene Ther 2016;23:107—13.

[47] Kemény N, Brown K, Covey A, Kim T, Bhargava A, Brody L, et al. Phase I, open-label, dose-escalating study of a geneti-
cally engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver. Hum Gene Ther 2006;17:1214—24.

[49] Mace AT, Ganly I, Soutar DS, Brown SM. Potential for efficacy of the oncolytic herpes simplex virus 1716 in patients with oral squamous carcinoma. Head Neck 2008;30:1045—51.

[50] Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 2000;7:867—74.

[51] Senzer NN, Kaufman HL, Amatruda T, Nemunaitis M, Reid T, Daniels G, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 2009;27:5763—71.

[52] Harrington KJ, Hingorani M, Tanay MA, Hickey J, Bhide SA, Clarke PM, et al. Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck. Clin Cancer Res 2010;16:4005—15.

[53] Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 2015;33:2780—8.

[54] Fujimoto Y, Mizuno T, Sugiuura S, Goshima F, Kohno S, Nakashima T, et al. Intratumoral injection of herpes simplex virus HF10 in recurrent head and neck squamous cell carcinoma. Acta Otolaryngol 2006;126:1115—7.

[55] Nakao A, Kasuya H, Sahuya T, Nomura N, Kanzaki A, Misawa M, et al. A phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancreatic cancer. Cancer Gene Ther 2011;18:167—75.

[56] Rajani K, Parrish C, Kottke T, Thompson J, Zaidi S, Ilett L, et al. Combination therapy with reovirus and anti-PD-1 blockade controls tumor growth through innate and adaptive immune responses. Mol Ther 2016;24:166—74.

[57] Madan RA, Mohibbashi M, Arlen PM, Vergati M, Rauckhorst M, Steinberg SM, et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 2012;13:501—8.

[58] Puzanov I, Milhem M, Andtbacka RH, Minor D, Hamid O, Li A, et al. Primary analysis of a phase Ib multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma. ASCO annual meeting 2014, abstract 9029.

[59] Sartorelli AC. The 1985 Walter Hubert lecture: malignant cell differentiation as a potential therapeutic approach. Br J Cancer 1985;52:293—302.

[60] Tanaka M, Levy J, Terada M, Breslow R, Rifkind RA, Marks PA. Induction of erythroid differentiation in murine virus infected erythroleukemia cells by highly polar compounds. Proc Natl Acad Sci U S A 1975;72:1003—6.

[61] Egorin MJ, Sigman LM, Van Echo DA, Forrest A, Whitacre MY, Aisner J. Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion. Cancer Res 1987;47:617—23.

[62] Yura Y, Kondo Y, Iga H, Harada K, Fujimoto H, Yanagawa T, et al. Enhanced replication of herpes simplex virus by hexamethylene bisacetamide. J Natl Cancer Inst 1991;83:186—9.

[63] McFarlane M, Daksis JI, Preston CM. Hexamethylene bisacetamide stimulates herpes simplex virus immediate early gene expression in the absence of trans-induction by Vmw65. J Gen Virol 1992;73:285—92.

[64] Naito S, Obayashi S, Sumi T, Iwai S, Nakazawa M, Ikuta K, et al. Enhancement of antitumor activity of herpes simplex virus gamma134.5-deficient mutant for oral squamous cell carcinoma cells by hexamethylene bisacetamide. Cancer Gene Ther 2006;13:780—91.